• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi , Feb. 10

RANBAXY Laboratories Ltd has signed a research agreement with the Institute of Nuclear Medical and Allied Sciences (INMAS) for screening and evaluation of formulations and New Drug Delivery Systems (NDDS) using Gamma Scintigraphy.

INMAS has been working on pharmaceutical applications of nuclear medicine, known as Pharmaco Scintigraphy and is under the Defence Research Development Organisation. The studies are undertaken to provide a "route map" for the development of molecules, utilised to visualise precisely where oral, pulmonary and other technologies are delivering drugs. The method is a very powerful, efficient and cost-effective study design for developing oral products and facilitates better candidate selection.

Ranbaxy's foray into NDDS has led to proprietary "platform technologies" resulting in a number of products under development.

More Stories on : Research & Development | Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Ranbaxy enters into research pact with INMAS

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line